Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2006

View Archived Issues

Volociximab well tolerated in phase II trials

Phase I studies of ADH-1 in patients with solid tumors reported

Denosumab progresses to phase II investigation in cancer patients

Pfizer reports on a novel COX-2 inhibitor with peripheral selectivity

New phase IIa results for allergy vaccine CYT003-QbG10

Pfizer responds to negative Lipitor publicity

Phase II/III results for MN-305 in GAD

Update on study of Aptivus in treatment-naive HIV patients

Novozymes to acquire Delta Biotechnology

Sunesis earns preclinical milestone payment in BACE collaboration with Merck

Avigen to study AV-411 for neuropathic pain

IND approval for study of Tectin

MB-06322, a fructose-1,6-bisphosphatase inhibitor, effective in rat models of type 2 diabetes

Novel alpha7 nAChR agonist for cognitive deficits in schizophrenia described by Pfizer

Bcl-2 antagonists show promise in chronic lymphocytic leukemia

Administration of MVA-5T4 feasible in renal cell carcinoma, colorectal cancer

Amendments approved for TRIUMPH study of treprostinil

NDA submission planned for VQD-001 for leishmaniasis

Metaglidasen begins phase II/III study in type 2 diabetes

Soliris meets endpoints with statistical significance in second phase III PNH study

New agents for treating diabetes and other endocrine disorders disclosed in recent patents

Novel antiinfective drugs disclosed in recent patent literature

Recent patents disclose new anti-HCV compounds

Wellbutrin XL approved for prevention of seasonal major depressive episodes

Panitumumab granted priority review for metastatic colorectal cancer

Priority review granted for Saforis in oral mucositis

Pharmion's filing for i.v. dosing of Vidaza accepted for filing

Glycosphingolipid synthesis inhibitor, Genz-123346, improves glucose control and insulin sensitivity

SB-509 is well tolerated in phase I clinical trials

N-Gene presents positive phase II results for BGP-15, its new insulin sensitizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...